The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19
Medicine
[키워드] ACE2
Administered
administration
Alter
Anti-inflammatory
anti-inflammatory drug
anti-SARS-CoV-2
Anti-viral
Anticoagulant
Antithrombotic
applicability
approach
ARDS
binding
Blood
complement
Complication
Corticosteroid
COVID-19
COVID-19 disease severity
COVID-19 severity
Cytokine storm
death case
death rate
Deleterious
derivatives
detrimental
Dexamethasone
diabetics
disease
downregulation
drug
early stage
ENhance
Evidence
exacerbated
feasible
fibrinolytic
global healthcare
glucocorticoid
glucocorticoid dexamethasone
groups
heparin
highlight
hyperglycemia
hypertensive patients
IL-6
immune responses
impairing
Inflammation
initial
Invasive mechanical ventilation
LTB
medical condition
modulate
Mounting
Occurrence
Patient
presenting
Prominent
Protein
reduce
required
respiratory
risk
SARS-CoV-2
secretion
severe COVID-19 patients
severe patients
significantly
sodium
spike
standard treatment
therapy
Treatment
upregulated
viral clearance
viral infection
viral infectivity
[DOI] 10.3389/fmed.2021.615333 PMC 바로가기 [Article Type] Medicine
[DOI] 10.3389/fmed.2021.615333 PMC 바로가기 [Article Type] Medicine